Overall rank by patents
#41,593
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Mimetogen Pharmaceuticals, Inc.
USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, active 2015–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07K (PEPTIDES).
6
Total patents granted
5
CPC technology areas
20.8
Avg claims per patent
-50%
5-year filing velocity
The verdict
Mimetogen holds 6 US patents across 5 technology areas, rank #41,593 of 50,000 tracked assignees.
- #41,593
- of 50,000 US assignees by volume
- Top 55%
- by Innovation Score (33.8/100)
- 20.8
- avg claims per patent
- -50%
- filing velocity, last 5 yrs
Portfolio overview
Mimetogen Pharmaceuticals, Inc. has been granted 6 US utility patents between 2015 and 2023, placing Mimetogen Pharmaceuticals, Inc. at rank #41,593 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.8 claims per patent with primary concentration in C07K (PEPTIDES). As a Foreign Corporation, Mimetogen Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Mimetogen sits between Middle Tennessee State University (6 patents, rank #41,589) and Miramar LABS, Inc. (6 patents, rank #41,597) - the closest US assignees by grant volume. The composite Innovation Score of 33.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 2 grants, compared with 4 in the 2015–2019 window, a -50% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Mimetogen Pharmaceuticals, Inc.'s 20.8 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Mimetogen Pharmaceuticals, Inc. against peers pursuing similar technology classes.
Who files at Mimetogen's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Middle Tennessee…
MIDDLE TENNESSEE STATE UNIVERSITY
6 patents
- Midwest Industria…
MIDWEST INDUSTRIAL SUPPLY, INC.
6 patents
- MIH Water Treatme…
MIH WATER TREATMENT, INC.
6 patents
- Millrock Technolo…
MILLROCK TECHNOLOGY, INC.
6 patents
- Minicare B V
MINICARE B.V.
6 patents
- MIPS
MIPS Technologies, Inc.
6 patents
- Miraclon
MIRACLON CORPORATION
6 patents
- Miramar LABS
MIRAMAR LABS, INC.
6 patents
- Mimetogen Pharmac… ◀
MIMETOGEN PHARMACEUTICALS, INC.
6 patents
What this shows Mimetogen holds 6 patents at rank #41,593, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Mimetogen
By rank, the assignees closest to #41,593 in granted patent volume.
- Middle Tennessee State University #41,589 · 6 patents
- Midwest Industrial Supply, Inc. #41,590 · 6 patents
- MIH Water Treatment, Inc. #41,591 · 6 patents
- Millrock Technology, Inc. #41,592 · 6 patents
- Minicare B.v. #41,594 · 6 patents
- MIPS Technologies, Inc. #41,595 · 6 patents
- Miraclon Corporation #41,596 · 6 patents
- Miramar LABS, Inc. #41,597 · 6 patents
Leaders in C07K (Peptides)
Other assignees with the most granted patents in Mimetogen's primary technology class.
- The Regents Of The University Of California 894 in class
- Regeneron Pharmaceuticals, Inc. 824 in class
- Immatics Biotechnologies Gmbh 678 in class
- Genentech, Inc. 565 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 513 in class
- The Trustees Of The University Of Pennsylvania 501 in class
- Novartis Ag 407 in class
- The Board Of Trustees Of The Leland Stanford Junior University 400 in class
Mimetogen's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
34 Top 55% higher than 45% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 33.3% |
| 2017 | 1 | 16.7% |
| 2018 | 1 | 16.7% |
| 2021 | 1 | 16.7% |
| 2023 | 1 | 16.7% |
Which technologies does Mimetogen Pharmaceuticals, Inc. patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Declining
Frequently Asked Questions
How many patents does Mimetogen Pharmaceuticals, Inc. hold?
Mimetogen Pharmaceuticals, Inc. holds 6 US granted patents filed between 2015 and 2023, spanning 5 technology areas.
What is Mimetogen Pharmaceuticals, Inc.'s Innovation Score?
Mimetogen Pharmaceuticals, Inc. has an Innovation Score of 33.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Mimetogen Pharmaceuticals, Inc. focus on?
Mimetogen Pharmaceuticals, Inc.'s top technology area is C07K (PEPTIDES) with 6 patents. The company has filed patents in 5 CPC subclasses total.
Is Mimetogen Pharmaceuticals, Inc.'s patent filing rate increasing or decreasing?
Mimetogen Pharmaceuticals, Inc.'s recent filing velocity is -50% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Mimetogen Pharmaceuticals, Inc.'s patents?
Mimetogen Pharmaceuticals, Inc.'s patents average 20.8 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Mimetogen Pharmaceuticals, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Mimetogen's 6 grants land it in the top 55% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Mimetogen ranks #41,593 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C07K - see who else leads that technology area. C07K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.